Creative Medical Technology Holdings (CELZ) Non-Current Assets (2016 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Non-Current Assets of $381658.0 for Q1 2026, down 24.16% year-over-year from $503263.0 in Q1 2025, and down 7.03% quarter-over-quarter from $410511.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Non-Current Assets (2016 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Non-Current Assets for 11 consecutive years, with $381658.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 24.16% year-over-year to $381658.0; the TTM figure through Mar 2026 stood at $1.7 million (down 13.8% YoY), while the FY2025 annual figure was $410511.0, down 23.1% from the prior year.
- Non-Current Assets eased to $381658.0 in Q1 2026 per CELZ's latest filing, from $410511.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $556479.0 in Q3 2024 and bottomed at $381658.0 in Q1 2026.
- Historically, Non-Current Assets has averaged $453937.0 across 5 years, with a median of $444292.0 in 2023.
- Annual changes were most pronounced in 2025 — Non-Current Assets increased 22.49% — and 2026, when it slipped 24.16%.
- Creative Medical Technology Holdings' Non-Current Assets stood at $438876.0 in 2022, then rose by 1.23% to $444292.0 in 2023, then advanced by 20.16% to $533840.0 in 2024, then retreated by 23.1% to $410511.0 in 2025, then fell by 7.03% to $381658.0 in 2026.
- Business Quant data shows CELZ's Non-Current Assets at $381658.0 in Q1 2026, $410511.0 in Q4 2025, and $441462.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | 358,740.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 358,740.00 |
| Mar 31, 2026 | 381,658.00 |
| Dec 31, 2025 | 410,511.00 |
| Sep 30, 2025 | 441,462.00 |
| Jun 30, 2025 | 472,521.00 |
| Mar 31, 2025 | 503,263.00 |
| Dec 31, 2024 | 533,840.00 |
| Sep 30, 2024 | 556,479.00 |
| Jun 30, 2024 | 385,750.00 |
| Mar 31, 2024 | 415,021.00 |
| Dec 31, 2023 | 444,292.00 |
| Sep 30, 2023 | 469,813.00 |
| Jun 30, 2023 | 392,834.00 |
| Mar 31, 2023 | 415,855.00 |
| Dec 31, 2022 | 438,876.00 |
| Sep 30, 2022 | 461,897.00 |
| Jun 30, 2022 | 484,918.00 |
| Mar 31, 2022 | 507,939.00 |
| Dec 31, 2021 | 530,960.00 |
| Sep 30, 2021 | 553,982.00 |